<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To clarify the clinical characteristics of type 2 diabetic patients with non-alcoholic <z:hpo ids='HP_0001397'>fatty liver</z:hpo> disease (NAFLD) and to assess whether NAFLD is related to <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">angiopathy</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: The study included 388 Japanese type 2 diabetic outpatients without <z:hpo ids='HP_0006562'>viral hepatitis</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The main outcome measures were <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">angiopathy</z:e> and NAFLD </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: The 388 subjects were divided into two subgroups based on alcohol consumption </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0001397'>Fatty liver</z:hpo> was recognized in 36 of the 142 drinking patients (25%) </plain></SENT>
<SENT sid="5" pm="."><plain>There was no association of <z:hpo ids='HP_0001397'>fatty liver</z:hpo> disease with diabetic macro- or <z:e sem="disease" ids="C0155765" disease_type="Disease or Syndrome" abbrv="">microangiopathy</z:e> in these patients </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0001397'>Fatty liver</z:hpo> disease (namely, NAFLD) was recognized in 77 of the 246 non-drinking patients (31%) </plain></SENT>
<SENT sid="7" pm="."><plain>Type 2 diabetic patients with NAFLD had a significantly younger age, higher body mass index level, higher levels of HbA1c, total cholesterol and <z:chebi fb="0" ids="17855">triglyceride</z:chebi>, lower <z:chebi fb="0" ids="47775">HDL-C</z:chebi> level, higher prevalence rates of <z:hpo ids='HP_0003124'>hypercholesterolemia</z:hpo> and <z:hpo ids='HP_0001513'>obesity</z:hpo> than counterparts without NAFLD </plain></SENT>
<SENT sid="8" pm="."><plain>In addition, individuals in the elderly (â‰¥65 years) non-drinking group with NAFLD had a significantly higher prevalence rates of <z:e sem="disease" ids="C1504375" disease_type="Disease or Syndrome" abbrv="">diabetic macroangiopathy</z:e>, <z:e sem="disease" ids="C0010068" disease_type="Disease or Syndrome" abbrv="">coronary heart disease</z:e> and thicker intima-media thickness level than their counterparts without NAFLD </plain></SENT>
<SENT sid="9" pm="."><plain>The logistic regression analysis showed that NAFLD is an independent predictor of <z:e sem="disease" ids="C1504375" disease_type="Disease or Syndrome" abbrv="">diabetic macroangiopathy</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Conclusion: NAFLD was associated with an increased prevalence of <z:e sem="disease" ids="C1504375" disease_type="Disease or Syndrome" abbrv="">diabetic macroangiopathy</z:e> and <z:e sem="disease" ids="C0010068" disease_type="Disease or Syndrome" abbrv="">coronary heart disease</z:e> in elderly patients </plain></SENT>
<SENT sid="11" pm="."><plain>In addition, NAFLD is an independent predictor for <z:e sem="disease" ids="C1504375" disease_type="Disease or Syndrome" abbrv="">diabetic macroangiopathy</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>These findings suggest that type 2 diabetic patients with NAFLD should be considered as a high risk group for developing <z:e sem="disease" ids="C1096293" disease_type="Disease or Syndrome" abbrv="">macroangiopathy</z:e>, even if <z:e sem="disease" ids="C1096293" disease_type="Disease or Syndrome" abbrv="">macroangiopathy</z:e> is not clinically detected </plain></SENT>
</text></document>